Onatasertib

Cat. No.: 0225LY-0606

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, HPLC, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Onatasertib is an oral mTOR kinase inhibitor (IC50: 16 nM) with over 150-fold selectivity over PI3K-alpha; it holds potential as an antitumor treatment by hindering cell proliferation and triggering apoptosis.

Synonym: CC223; CC 223; 1228013-30-6; 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one; 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one; Pyrazino[2,3-b]pyrazin-2(1H)-one, 3,4-dihydro-7-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-(trans-4-methoxycyclohexyl)-; 7-(6-(2-Hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one

CAS No.: 1228013-30-6

Compound CID: 58298316

Formula: C₂₁H₂₇N₅O₃

Formula Weight: 397.47

Specification

Targets&IC50: mTOR: 16 nM

Relative Density: 1.37 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Onatasertib can be used in clinical pharmacology research to evaluate the impact of dual mTORC1 and mTORC2 blockade in advanced malignancies.